155 related articles for article (PubMed ID: 15808481)
1. 6-(2-Furanyl)-9H-purin-2-amine derivatives as A2A adenosine antagonists.
Kiselgof E; Tulshian DB; Arik L; Zhang H; Fawzi A
Bioorg Med Chem Lett; 2005 Apr; 15(8):2119-22. PubMed ID: 15808481
[TBL] [Abstract][Full Text] [Related]
2. 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: highly potent, orally active, adenosine A2A antagonists. Part 1.
Matasi JJ; Caldwell JP; Zhang H; Fawzi A; Cohen-Williams ME; Varty GB; Tulshian DB
Bioorg Med Chem Lett; 2005 Aug; 15(16):3670-4. PubMed ID: 15978806
[TBL] [Abstract][Full Text] [Related]
3. 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs as adenosine A2A antagonists: the successful reduction of hERG activity. Part 2.
Matasi JJ; Caldwell JP; Zhang H; Fawzi A; Higgins GA; Cohen-Williams ME; Varty GB; Tulshian DB
Bioorg Med Chem Lett; 2005 Aug; 15(16):3675-8. PubMed ID: 15982882
[TBL] [Abstract][Full Text] [Related]
4. 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.
Lenzi O; Colotta V; Catarzi D; Varano F; Poli D; Filacchioni G; Varani K; Vincenzi F; Borea PA; Paoletta S; Morizzo E; Moro S
J Med Chem; 2009 Dec; 52(23):7640-52. PubMed ID: 19743865
[TBL] [Abstract][Full Text] [Related]
5. 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
Minetti P; Tinti MO; Carminati P; Castorina M; Di Cesare MA; Di Serio S; Gallo G; Ghirardi O; Giorgi F; Giorgi L; Piersanti G; Bartoccini F; Tarzia G
J Med Chem; 2005 Nov; 48(22):6887-96. PubMed ID: 16250647
[TBL] [Abstract][Full Text] [Related]
6. Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.
Peng H; Kumaravel G; Yao G; Sha L; Wang J; Van Vlijmen H; Bohnert T; Huang C; Vu CB; Ensinger CL; Chang H; Engber TM; Whalley ET; Petter RC
J Med Chem; 2004 Dec; 47(25):6218-29. PubMed ID: 15566292
[TBL] [Abstract][Full Text] [Related]
7. Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists.
Vu CB; Shields P; Peng B; Kumaravel G; Jin X; Phadke D; Wang J; Engber T; Ayyub E; Petter RC
Bioorg Med Chem Lett; 2004 Oct; 14(19):4835-8. PubMed ID: 15341934
[TBL] [Abstract][Full Text] [Related]
8. Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites.
Michielan L; Bolcato C; Federico S; Cacciari B; Bacilieri M; Klotz KN; Kachler S; Pastorin G; Cardin R; Sperduti A; Spalluto G; Moro S
Bioorg Med Chem; 2009 Jul; 17(14):5259-74. PubMed ID: 19501513
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of novel 7-imino-2-thioxo-3,7-dihydro-2H-thiazolo [4,5-d] pyrimidine derivatives as adenosine A2A receptor antagonists.
Luthra PM; Mishra CB; Jha PK; Barodia SK
Bioorg Med Chem Lett; 2010 Feb; 20(3):1214-8. PubMed ID: 20018509
[TBL] [Abstract][Full Text] [Related]
10. Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists.
Shah U; Boyle CD; Chackalamannil S; Neustadt BR; Lindo N; Greenlee WJ; Foster C; Arik L; Zhai Y; Ng K; Wang S; Monopoli A; Lachowicz JE
Bioorg Med Chem Lett; 2008 Jul; 18(14):4199-203. PubMed ID: 18562199
[TBL] [Abstract][Full Text] [Related]
11. Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonists.
Baraldi PG; Saponaro G; Aghazadeh Tabrizi M; Baraldi S; Romagnoli R; Moorman AR; Varani K; Borea PA; Preti D
Bioorg Med Chem; 2012 Jan; 20(2):1046-59. PubMed ID: 22204739
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
[TBL] [Abstract][Full Text] [Related]
13. Characterization of A2A adenosine receptors in human lymphocyte membranes by [3H]-SCH 58261 binding.
Varani K; Gessi S; Dalpiaz A; Ongini E; Borea PA
Br J Pharmacol; 1997 Sep; 122(2):386-92. PubMed ID: 9313951
[TBL] [Abstract][Full Text] [Related]
14. Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides.
Gillespie RJ; Bamford SJ; Clay A; Gaur S; Haymes T; Jackson PS; Jordan AM; Klenke B; Leonardi S; Liu J; Mansell HL; Ng S; Saadi M; Simmonite H; Stratton GC; Todd RS; Williamson DS; Yule IA
Bioorg Med Chem; 2009 Sep; 17(18):6590-605. PubMed ID: 19695884
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and SAR studies of trisubstituted purinones as potent and selective adenosine A2A receptor antagonists.
Shao Y; Cole AG; Brescia MR; Qin LY; Duo J; Stauffer TM; Rokosz LL; McGuinness BF; Henderson I
Bioorg Med Chem Lett; 2009 Mar; 19(5):1399-402. PubMed ID: 19181527
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression.
Hodgson RA; Bertorelli R; Varty GB; Lachowicz JE; Forlani A; Fredduzzi S; Cohen-Williams ME; Higgins GA; Impagnatiello F; Nicolussi E; Parra LE; Foster C; Zhai Y; Neustadt BR; Stamford AW; Parker EM; Reggiani A; Hunter JC
J Pharmacol Exp Ther; 2009 Jul; 330(1):294-303. PubMed ID: 19332567
[TBL] [Abstract][Full Text] [Related]
17. Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches.
Richardson CM; Gillespie RJ; Williamson DS; Jordan AM; Fink A; Knight AR; Sellwood DM; Misra A
Bioorg Med Chem Lett; 2006 Dec; 16(23):5993-7. PubMed ID: 16971117
[TBL] [Abstract][Full Text] [Related]
18. Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
Vu CB; Pan D; Peng B; Kumaravel G; Smits G; Jin X; Phadke D; Engber T; Huang C; Reilly J; Tam S; Grant D; Hetu G; Petter RC
J Med Chem; 2005 Mar; 48(6):2009-18. PubMed ID: 15771443
[TBL] [Abstract][Full Text] [Related]
19. 2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationships.
Slee DH; Moorjani M; Zhang X; Lin E; Lanier MC; Chen Y; Rueter JK; Lechner SM; Markison S; Malany S; Joswig T; Santos M; Gross RS; Williams JP; Castro-Palomino JC; Crespo MI; Prat M; Gual S; Díaz JL; Jalali K; Sai Y; Zuo Z; Yang C; Wen J; O'Brien Z; Petroski R; Saunders J
J Med Chem; 2008 Mar; 51(6):1730-9. PubMed ID: 18307293
[TBL] [Abstract][Full Text] [Related]
20. Methylene amine substituted arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists.
Shook BC; Rassnick S; Hall D; Rupert KC; Heintzelman GR; Hansen K; Chakravarty D; Bullington JL; Scannevin RH; Magliaro B; Westover L; Carroll K; Lampron L; Russell R; Branum S; Wells K; Damon S; Youells S; Li X; Osbourne M; Demarest K; Tang Y; Rhodes K; Jackson PF
Bioorg Med Chem Lett; 2010 May; 20(9):2864-7. PubMed ID: 20347304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
